Sankyo Licenses Cardiovascular Disease Drug Candidate KAI-9803 from KAI Pharmaceuticals.Tokyo, Japan, Jan 11, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Daiichi Sankyo announced on January 10 that its wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. Sankyo and US company KAI Pharmaceuticals have entered into a licensing agreement on KAI-9803, a drug candidate developed by KAI Pharmaceuticals. Under the agreement terms, Sankyo and KAI Pharmaceuticals will collaborate in the worldwide development and commercialization of KAI-9803. In addition, Sankyo will make an initial payment of $20 million to KAI Pharmaceuticals. KAI-9803, a peptide compound, is intended for the treatment of acute myocardial infarction acute myocardial infarction (  ·kyōōtˑ mī·ō·karˑ·dē· and cerebral infarction cerebral infarctionn. See stroke. cerebral infarction, n the blockage of the flow of blood to the cerebrum, causing or resulting in brain tissue death. . Currently, KAI Pharmaceuticals is conducting phase I and II clinical trials in the US. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion